# Does Hawaii Med-QUEST Cover Wegovy or Zepbound? Not for Weight Loss

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-11-07

Canonical page: https://glpwatchdog.org/research/hawaii-medicaid-glp1-coverage

> Hawaii Medicaid excludes GLP-1s for weight loss, and 2026 bills to lift that exclusion say the state keeps Saxenda, Wegovy and Zepbound out in most situations. What the bills proposed, what could not be confirmed about heart and sleep apnea uses, and how to ask a QUEST plan.

## Key points

- Weight-loss drugs are not covered: AlohaCare's QUEST page names them as an excluded category.
- Two 2026 bills said the state excludes Saxenda, Wegovy and Zepbound in most situations and proposed coverage with no prior authorization.
- Only the introduced texts and one House draft appear on the legislature's server, so neither bill can be shown to have passed.
- No published QUEST criteria for Wegovy's heart or MASH uses or Zepbound's sleep apnea use could be found.
- Plan appeals are due within 60 days of a denial, with 90 to 120 days after that to seek a state hearing.

No. As of November 2026, Hawaii’s Med-QUEST Medicaid program will not pay for Wegovy, Zepbound or Saxenda when the goal is weight loss; AlohaCare, one of its health plans, states plainly that “drugs for weight loss” are not covered.[1] Bills filed in the 2026 legislature describe the state as excluding these drugs “in most situations,” but no published Hawaii rule we could find says which situations qualify.[2][3]

> **About this article.** This page rests on a thinner record than most of our state guides, and it says so. It draws on AlohaCare’s QUEST pharmacy page and the 2026 House and Senate bills, as they stood on November 1, 2026, rechecked November 7, 2026. The Med-QUEST Division’s own website could not be opened, so its drug rules could not be read, and the legislature’s bill status pages were blocked the same way. Nothing below fills those gaps with a guess. To compare states, use the [state Medicaid GLP-1 checker](https://glpwatchdog.org/tools/state-medicaid-glp1-checker).

## Does Hawaii Medicaid cover Wegovy for weight loss?

It does not. Under federal law, any state may leave weight-loss drugs out of Medicaid, and Hawaii does.[4] AlohaCare’s QUEST page lists weight loss alongside erectile dysfunction, infertility and cosmetic uses as drug categories it will not cover.[1] The same page says the plan covers every medically necessary drug that Med-QUEST covers, so the exclusion traces back to the state program, not one plan’s choice.[1]

The 2026 bills confirm it from the other side. Both open with findings that the Department of Human Services has chosen to keep Saxenda, Wegovy and Zepbound out of Medicaid coverage in most situations.[2][3] Our explainer on [how Medicaid treats Ozempic and Wegovy](https://glpwatchdog.org/research/does-medicaid-cover-ozempic-and-wegovy) covers the federal rule behind that choice.

## What would the 2026 GLP-1 bills have changed?

House Bill 2456 and Senate Bill 3195 aimed to end the exclusion. Both would have made Medicaid members eligible for FDA-approved GLP-1s used for weight loss, prescribed by a practitioner, with no prior authorization.[2][3] The House version, as amended in committee, dropped the original’s reference to Medicare Part D and added a condition that the patient take part in a lifestyle program supporting long-term weight maintenance.[2][13]

*Hawaii’s 2026 GLP-1 Medicaid bills, from the bill texts on the legislature’s document server, read November 1, 2026*

| Feature | H.B. 2456, H.D. 1 | S.B. 3195, as introduced |
| --- | --- | --- |
| Who would qualify | Medicaid prescription drug recipients | Medicaid and Medicare Part D drug recipients |
| Prior authorization | Not required | Not required |
| Lifestyle program | Required | Not mentioned |
| Temporary rules due | By August 1, 2026 | By August 1, 2026 |
| Permanent rules due | By January 1, 2028 | By January 1, 2028 |
| Funding | Appropriation amount left blank | Not stated in the text read |

Whether either bill moved further is not something we can state. The legislature’s document server holds only the introduced texts and the House committee draft, with no later Senate or conference draft for either, and the bill status pages could not be opened.[2][3] The House bill named July 1, 2026 as its effective date; AlohaCare’s page, read four months after that date, still excludes weight-loss drugs.[1][2] Any 2027 bill would start the process again.

## Does Hawaii Medicaid cover Wegovy for heart disease or Zepbound for sleep apnea?

That is the open question. Wegovy is FDA-approved to lower the risk of heart attack and stroke in adults with heart disease and excess weight, and to treat the liver disease MASH; Zepbound carries approval for moderate to severe sleep apnea when obesity is also present.[6][7] Many state Medicaid programs that exclude weight loss now cover one or more of those uses with prior authorization.

In Hawaii, the bills’ phrase “in most situations” suggests some uses are covered, but neither bill names them.[2] We found no Med-QUEST or plan criteria for any of the three uses. One plan does treat Zepbound as a drug it reviews: ‘Ohana Health Plan’s QUEST Integration drug list update for September 1, 2026 tells pharmacies “PA Required. Use Zepbound KwikPen” and applies that pen rule “for all indications,” without saying which indications those are.[14] AlohaCare’s exclusion is worded around weight loss, which leaves room for a request based on another diagnosis.[1] A prescriber treating sleep apnea or established heart disease can file one and see how the plan rules. Our pages on [Zepbound for sleep apnea](https://glpwatchdog.org/research/zepbound-for-sleep-apnea) and [GLP-1s for MASH](https://glpwatchdog.org/research/glp1-and-fatty-liver-mash) explain the evidence behind those approvals.

*What is and is not confirmed for Hawaii Medicaid GLP-1 coverage, as of November 7, 2026*

| Use | Status | Basis |
| --- | --- | --- |
| Weight loss alone | Not covered | AlohaCare QUEST page; both 2026 bills |
| Heart risk (Wegovy) | Not confirmed | No published criteria found |
| MASH (Wegovy) | Not confirmed | No published criteria found |
| Sleep apnea (Zepbound) | Not confirmed | No published criteria found |
| Teens with obesity | Not confirmed | No published criteria found; federal child-health rules apply |
| Type 2 diabetes | Not confirmed from a document we could read | Check the plan’s drug finder |

## Can a teenager on QUEST get a GLP-1?

Wegovy and Saxenda are both approved for obesity from age 12, Saxenda only above 60 kg.[6][8] Federal child-health rules, known as EPSDT, require Medicaid to provide necessary treatment for members under 21 whether or not the state plan covers it.[5] We found no Hawaii document applying that rule to GLP-1s. A family can still ask the plan to review a request on that basis, with records showing why the drug is needed. Our review of [GLP-1 drugs in teenagers](https://glpwatchdog.org/research/glp1-drugs-in-teenagers) covers what the trials found.

## How do you ask for coverage or appeal in Hawaii?

Start with the plan. AlohaCare takes pharmacy prior authorization requests from prescribers at 808-973-7418 or 866-973-7418, by fax at 1-866-728-0233 or 1-877-252-5224, or electronically, which it prefers.[1] Members of other QUEST plans should use the numbers on their own card.

Federal rules set the appeal clock for Medicaid health plans. A member has 60 days from a denial notice to appeal to the plan, and then at least 90 and at most 120 days from the plan’s decision to ask the state for a fair hearing.[9][10] The notice gives the exact dates. Appeals stand on the strongest ground for a non-weight use with a documented diagnosis. Our walkthrough of [prior authorization and appeals](https://glpwatchdog.org/research/glp1-prior-authorization-and-appeals) covers what to include, and the [Hawaii state page](https://glpwatchdog.org/states/hawaii) collects the Medicaid basics.

## What can you do if Med-QUEST won’t pay?

Self-pay is the fallback, since Lilly’s copay card terms exclude anyone enrolled in Medicaid.[11] In the prices we track, Novo Nordisk sells most Wegovy pen doses for $349 a month to self-pay patients, and Lilly’s Zepbound runs from $299 at the starting dose to $449 at higher doses refilled on time.[11][12] Check each program’s terms on government coverage before enrolling, and compare them in our list of the [cheapest GLP-1 options without insurance](https://glpwatchdog.org/research/cheapest-glp1-without-insurance).

## Frequently asked questions

### Does Hawaii Medicaid cover Wegovy?

Not for weight loss. As of November 2026, AlohaCare's QUEST page says drugs for weight loss are not covered, and 2026 bills describe the state as excluding Wegovy in most situations. No published Hawaii criteria were found for Wegovy's heart or liver uses.

### Does Hawaii Med-QUEST cover Zepbound for sleep apnea?

It is not confirmed. Zepbound is FDA-approved for moderate to severe sleep apnea in adults with obesity, but no Med-QUEST or QUEST plan criteria for that use could be found. A prescriber can file a prior authorization request based on the sleep apnea diagnosis and see how the plan rules.

### Did Hawaii pass a law to cover GLP-1s for weight loss?

Not that could be confirmed. House Bill 2456 and Senate Bill 3195 were filed in 2026 to require Medicaid coverage without prior authorization, but no later draft of either appears on the legislature's document server, and a QUEST plan still excluded weight-loss drugs in November 2026.

### What GLP-1 drugs did the Hawaii bills name?

Both bills named Saxenda, Wegovy and Zepbound as the GLP-1 drugs approved for weight loss that the Department of Human Services excludes in most situations. They would have covered any FDA-approved GLP-1 used for weight loss.

### What is the deadline to appeal a QUEST plan denial?

Federal rules give Medicaid health plan members 60 days from the denial notice to appeal to the plan. After the plan decides, the member has at least 90 and at most 120 days to request a state fair hearing. The exact dates are on the notice.

## References

1. AlohaCare AlohaCare QUEST (Medicaid) Formulary: provider pharmacy information. alohacare.org. 2026. https://alohacare.org/Providers/Formulary_QUEST
2. Hawaii State Legislature H.B. No. 2456, H.D. 1: A Bill for an Act Relating to Drugs for Weight Loss (2026). data.capitol.hawaii.gov. 2026. https://data.capitol.hawaii.gov/sessions/session2026/bills/HB2456_HD1_.HTM
3. Hawaii State Legislature S.B. No. 3195: A Bill for an Act Relating to Drugs for Weight Loss (2026). data.capitol.hawaii.gov. 2026. https://data.capitol.hawaii.gov/sessions/session2026/bills/SB3195_.HTM
4. United States Code 42 U.S.C. §1396r-8: Payment for covered outpatient drugs (Social Security Act §1927). Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/uscode/text/42/1396r-8
5. United States Code 42 U.S.C. §1396d: Definitions, including early and periodic screening, diagnostic, and treatment services (subsection r). Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/uscode/text/42/1396d
6. Novo Nordisk WEGOVY (semaglutide) injection and tablets: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
7. Eli Lilly and Company ZEPBOUND (tirzepatide) injection: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
8. Novo Nordisk SAXENDA (liraglutide) injection: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
9. Code of Federal Regulations 42 CFR §438.402: Grievance and appeal systems, general requirements. eCFR. 2026. https://www.ecfr.gov/current/title-42/section-438.402
10. Code of Federal Regulations 42 CFR §438.408: Resolution and notification of grievances and appeals. eCFR. 2026. https://www.ecfr.gov/current/title-42/section-438.408
11. Eli Lilly and Company Zepbound savings and self-pay options, with card terms. zepbound.lilly.com. 2026. https://zepbound.lilly.com/savings
12. Novo Nordisk Wegovy savings offer. novocare.com. 2026. https://www.novocare.com/obesity/products/wegovy/savings-offer.html
13. Hawaii State Legislature H.B. No. 2456, as introduced: A Bill for an Act Relating to Drugs for Weight Loss (2026). data.capitol.hawaii.gov. 2026. https://data.capitol.hawaii.gov/sessions/session2026/bills/HB2456_.HTM
14. ‘Ohana Health Plan ‘Ohana QUEST Integration Preferred Drug List Update (date of change September 1, 2026). ohanahealthplan.com. 2026. https://www.ohanahealthplan.com/content/dam/centene/wellcare/hi/pdfs/pdl/HI_Member_Letter_NOC_060926.pdf

---

Cite as: GLP Watchdog, Nora Bissett, "Does Hawaii Med-QUEST Cover Wegovy or Zepbound? Not for Weight Loss", published 2026-11-07. https://glpwatchdog.org/research/hawaii-medicaid-glp1-coverage

Canonical HTML page: https://glpwatchdog.org/research/hawaii-medicaid-glp1-coverage

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.